Home ›
Entities
› academia
› Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model
Research article (Clinical Drug Investigation, 2024) · cited 11× · AI/ML
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from an US Societal Perspective Model
Summary
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from an US Societal Perspective Model is a scholarly article[1].
Key Facts
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from an US Societal Perspective Model's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model. Retrieved May 24, 2026, from https://4ort.xyz/entity/cost-effectiveness-evaluation-of-oral-cgrp-antagonists-atogepant-and-rimegepant-for-the-preventative-treatment-of-episod
MLA“Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/cost-effectiveness-evaluation-of-oral-cgrp-antagonists-atogepant-and-rimegepant-for-the-preventative-treatment-of-episod.
BibTeX@misc{4ortxyz_cost-effectiveness-evaluation-of-oral-cgrp-antagonists-atogepant-and-rimegepant-for-the-preventative-treatment-of-episod_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model}}, year = {2026}, url = {https://4ort.xyz/entity/cost-effectiveness-evaluation-of-oral-cgrp-antagonists-atogepant-and-rimegepant-for-the-preventative-treatment-of-episod}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model — https://4ort.xyz/entity/cost-effectiveness-evaluation-of-oral-cgrp-antagonists-atogepant-and-rimegepant-for-the-preventative-treatment-of-episod (retrieved 2026-05-24)
